Table IV.
Associations between PIGC protein expression and clinical features.
| PIGC expression | ||||
|---|---|---|---|---|
| Factor | High (n=63) | Low (n=25) | χ2 value | P-value |
| Sex | 0.880 | 0.348 | ||
| Male | 42 | 14 | ||
| Female | 21 | 11 | ||
| Age, years | 0.503 | 0.478 | ||
| <60 | 33 | 11 | ||
| ≥60 | 30 | 14 | ||
| G stage | 1.267 | 0.260 | ||
| G1+G2 | 23 | 6 | ||
| G3+G4 | 40 | 19 | ||
| T stage | 0.329 | 0.566 | ||
| T1-T2 | 14 | 7 | ||
| T3-T4 | 49 | 18 | ||
| N stage | 5.099 | 0.024a | ||
| N0 | 19 | 14 | ||
| N1-N2 | 44 | 11 | ||
| M stage | 6.974 | 0.008a | ||
| M0 | 44 | 24 | ||
| M1 | 19 | 1 | ||
| TNM stage | 4.985 | 0.026a | ||
| I–II | 17 | 13 | ||
| III–IV | 46 | 12 | ||
a
P<0.05. PIGC, phosphatidylinositol glycan anchor biosynthesis class C; TNM, tumor node metastasis; G, grade.